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COMMENT Open Access
Moving pathogen genomics out of the lab
and into the clinic: what will it take?
Leila M. Luheshi1*, Sobia Raza1 and Sharon J. Peacock2
Editorial summary
Pathogen genomic analysis is a potentially
transformative new approach to the clinical and
public-health management of infectious diseases.
Health systems investing in this technology will
need to build infrastructure and develop policies
that ensure genomic information can be generated,
shared and acted upon in a timely manner.
The promise of pathogen genomics
Whole-genome sequencing (WGS) of specific patho-
gens and metagenomic sequencing of communities of
microbes have now been used in a wide range of clin-
ical and epidemiological research investigations of in-
fectious disease. WGS of a pathogen has enabled the
resolution of a methicillin-resistant Staphylococcus aur-
eus outbreak on a neonatal intensive care ward [1] and
the successful identification of sources of Pseudomonas
aeruginosa infections on a burns unit [2] and, most re-
cently, it has been deployed for the real-time surveillance
of the Ebola outbreak in West Africa [3]. Metagenomics
has been successfully used to characterise the strain of
Shiga-toxin-producing Escherichia coli (STEC) O104:H4
that was responsible for a pan-European outbreak [4] and
in a diagnostic context to identify rare neurological infec-
tions [5] and transplant-related infections [6]. These strik-
ing examples of the power of genomics in this field of
medicine have sparked considerable excitement within the
healthcare sector.
Moves are now afoot within a number of health sys-
tems to establish pathogen WGS infrastructure and ser-
vices to meet the ongoing need to manage infectious
disease at a national and international level. In the USA,
the Food and Drug Administration has developed Geno-
meTrakr (http://www.fda.gov/food/foodscienceresearch/
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wholegenomesequencingprogramwgs/ucm363134.htm),
a geographically distributed, multi-agency WGS-based
surveillance network for detecting and investigating food-
borne disease outbreaks. Similarly, Public Health England
is now routinely using WGS at its national microbiology
reference laboratory for Salmonella infection surveillance
and outbreak investigation [6]. Both of these programmes
have had notable successes in enhancing the effectiveness
of investigations of foodborne infectious disease outbreaks
(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6406
a3.htm?s_cid=mm6406a3_e) [7].
The ability of WGS to improve the sensitivity and
specificity of such challenging outbreak investigations
is acting as a strong driver for the implementation of
WGS services by public-health authorities worldwide.
Notably, the Global Microbial Identifier project (http://
www.globalmicrobialidentifier.org/People), which was
established to support the development of an international
system of genomics-based infectious disease surveillance,
has members from 42 nations.
A major challenge in the field is to find the optimal
solutions to bring the benefits of this new technology to
patients as quickly, effectively and equitably as possible.
These solutions are likely to vary widely between health
systems. Where genomics services need to be delivered
to large geographically dispersed populations with de-
volved political and health infrastructures, such as in the
USA, a distributed network approach might be the best
solution. By contrast, when dealing with smaller popula-
tions in countries (such as England) where a strong, cen-
tralised nationwide disease surveillance mechanism is in
place, building on this existing framework might be
more effective. Despite these geographical variations in
health-system organisation, some common principles
exist, which we have identified through our analysis of
pathogen genomics within the context of the English
health system [8]. These common principles will need to
be considered regardless of location.
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One size does not fit all
It is important that pathogen genomics services are con-
figured in a way that allows for flexibility. Providing gen-
omics infrastructure and skills that are responsive to the
diverse needs of clinicians and public-health practitioners
is essential, yet not straightforward. Clinical diagnostic or
time-sensitive investigations may require low-throughput,
‘on demand’ sequencing and automated analysis — on
benchtop or even portable sequencers — to deliver action-
able results to clinicians. Portable sequencing kits have,
for example, enabled ‘lab in a suitcase’ solutions to be de-
ployed for real-time genomic surveillance of the Ebola
virus in West Africa [3]. By contrast, larger scale, longitu-
dinal public health surveillance activities could be deliv-
ered using approaches with higher throughput but longer
turnaround times. An enormous variation also exists in
access to genomic technology and expertise across health
systems, as well as variation in the level of the underlying
need for genomics as a tool to manage infectious disease.
Those charged with management and commissioning of
infectious disease services within individual health systems
will, therefore, have to remain extremely flexible if they
are to navigate this complex landscape of supply, demand
and capability. It will be important to avoid over-investing
in technology that could rapidly become obsolete and rec-
ognise that the optimal configuration and location of gen-
omics services will vary according to local demand and
the availability of genomics skills and infrastructure, which
are also subject to rapid change.
Pathogen genomics is a team game
The most successful demonstrations of the capabilities
of pathogen genomics were the deciphering of the ori-
gins of the Middle East respiratory syndrome corona-
virus and the management of the Europe-wide 2011
STEC outbreak. These have also been excellent exam-
ples of the effectiveness of collaborations, which were
supported by openness and data sharing, that span
multiple geographies, fields of expertise and profes-
sional groups. As we move towards implementing these
advances across entire health systems, this collaborative
spirit needs to be harnessed and scaled up to deliver more
formalised networks for sharing knowledge and best prac-
tice. These networks will expedite national service deploy-
ment, accelerate future service development and provide
expert forums in which the arduous but essential task of
establishing the standards and benchmarks of service
quality can be undertaken. High-level strategic coordin-
ation and knowledge-sharing across health delivery orga-
nisations are equally essential. For example, synergy in the
development of pathogen genomics programmes across
animal and human health sectors will be needed to deliver
a ‘one-health’ approach to tackling many of the most
pressing zoonotic disease threats, such as avian influenza
and the spread of antimicrobial resistance from livestock
to humans, as well as the more commonplace but persist-
ent issue of foodborne illnesses.
Data — it’s time to go big
No large-scale genomics enterprise can hope to succeed
without effective data integration and sharing. In the
case of pathogen genomics for clinical or public health,
data integration will require the construction of dedi-
cated infrastructure (real or virtual) to collate, store,
analyse and share genomic, epidemiological and clinical
data across complex national and international health
systems. This integration will be particularly crucial to
enable the delivery of genomic epidemiology services, in
which the requirement for data sharing across locations
is fundamental and time (as in the 2015 Ebola out-
break) is very much of the essence. Data integration
and access will become equally central in diagnostic
microbiology, where having an accurate and readily ac-
cessible summary of genotype, phenotype and clinical
information for different pathogens is essential to de-
liver care to patients.
Notably, the Global Microbial Identifier (http://www.glo
balmicrobialidentifier.org/Workgroups#work-group-1) and
the Global Alliance for Genomic Health (https://genomic-
sandhealth.org/node/12703) projects are already demon-
strating that huge technical, regulatory and political efforts
will be required to overcome barriers imposed by the vary-
ing capabilities, legal systems and cultural frameworks of
different nations if transnational genomic and clinical data
integration is to be achieved. As an example, such barriers
led the Indonesian government to temporarily withdraw
from the Global Influenza Surveillance Network in 2007,
owing to concerns that, if data were shared, proprietary in-
terests would be exerted over the H5N1 strains [9]. The
same issues can also impose barriers to sharing and data
integration within individual health systems.
Staying ahead of the game
The application of genomics to infectious disease man-
agement is still in its infancy, and we currently lack the
background knowledge, as well as the technological cap-
ability, to deliver rapid, clinically actionable information
based on genomic analysis that can improve outcomes
for patients. This situation is fluid, as sequencing tech-
nology (in the form of devices that are increasingly more
portable, cost less and have a longer read capability) and
analysis (in the form of cloud computing, more efficient
metagenomic analysis and implementation of automated
analytic pipelines) continue to develop apace. However,
capitalising on the current rapid pace of innovation will
demand novel approaches to public–private cooperation
and co-development of the type seen with the Oxford
Nanopore Minion Access Programme, which puts new
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genomic technology in the hands of its users (including
those in the health system) at the earliest possible oppor-
tunity [10]. These efforts will also benefit from building
on the commendably open and collaborative approaches
for the development of knowledge and analytical methods
that are already being taken by many pathogen genomics
researchers. These collaborations will ensure that the
knowledge and expertise of these researchers are shared
rapidly with the clinical and public-health communities in
which their influence is most needed.
Most importantly, health systems must adapt to the
reality of rapid innovation in genomics. Current ap-
proaches to implementation of innovation in health sys-
tems are often characterised by pilots, trials and regulatory
hurdles so numerous that by the time they are completed
the technology is already becoming obsolete. These ap-
proaches must be replaced with more agile and stream-
lined approaches that are properly resourced and that
empower clinicians and scientists to operate services that
are being continuously updated and improved in light of
new knowledge and technology.
Conclusions
The path to successful pathogen genomic service delivery
in the health system is likely to be interrupted by a num-
ber of potentially unpredictable step-changes in techno-
logical innovation and discovery. It is vital that researchers
remain engaged in the process of frontline implementa-
tion over the coming years. Effective collaborations with
healthcare practitioners and policy-makers will be central
to catalysing the transformation of these innovations from
inspirational case studies to the core of a widely available
and routinely delivered genomics-enabled system of infec-
tious disease management.
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